Which has higher valuation & earnings, AVLN or INDV?

Indivior has higher revenue and earnings than Avalyn Pharma. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Avalyn Pharma N/A N/A N/A N/A N/A Indivior $1.24B 3.68 $210M $1.95 19.17

Which has preferable earnings and valuation, AVLN or TVTX?

Avalyn Pharma has higher earnings, but lower revenue than Travere Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Avalyn Pharma N/A N/A N/A N/A N/A Travere Therapeutics $490.73M 8.92 -$25.55M -$0.23 N/A

Does the media prefer AVLN or TVTX?

In the previous week, Travere Therapeutics had 14 more articles in the media than Avalyn Pharma. MarketBeat recorded 19 mentions for Travere Therapeutics and 5 mentions for Avalyn Pharma. Travere Therapeutics' average media sentiment score of 0.57 beat Avalyn Pharma's score of -0.50 indicating that Travere Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Avalyn Pharma 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Negative Travere Therapeutics 7 Very Positive mention(s) 4 Positive mention(s) 6 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better earnings and valuation, MANE or AVLN?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Veradermics N/A N/A N/A N/A N/A Avalyn Pharma N/A N/A N/A N/A N/A

Is MANE or AVLN more profitable?

Company Net Margins Return on Equity Return on Assets Veradermics N/A N/A N/A Avalyn Pharma N/A N/A N/A

Does the media prefer MANE or AVLN?

In the previous week, Avalyn Pharma had 1 more articles in the media than Veradermics. MarketBeat recorded 5 mentions for Avalyn Pharma and 4 mentions for Veradermics. Veradermics' average media sentiment score of -0.02 beat Avalyn Pharma's score of -0.50 indicating that Veradermics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Veradermics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Avalyn Pharma 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Negative

Which has preferable valuation & earnings, AVLN or AMRX?

Amneal Pharmaceuticals has higher revenue and earnings than Avalyn Pharma. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Avalyn Pharma N/A N/A N/A N/A N/A Amneal Pharmaceuticals $3.02B 1.45 $72.06M $0.38 36.08

Does the media prefer AVLN or AMRX?

In the previous week, Amneal Pharmaceuticals had 1 more articles in the media than Avalyn Pharma. MarketBeat recorded 6 mentions for Amneal Pharmaceuticals and 5 mentions for Avalyn Pharma. Amneal Pharmaceuticals' average media sentiment score of 0.30 beat Avalyn Pharma's score of -0.50 indicating that Amneal Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Avalyn Pharma 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Negative Amneal Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better earnings and valuation, AVLN or TWST?

Avalyn Pharma has higher earnings, but lower revenue than Twist Bioscience. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Avalyn Pharma N/A N/A N/A N/A N/A Twist Bioscience $376.57M 11.58 -$77.67M -$1.33 N/A

Does the media favor AVLN or TWST?

In the previous week, Twist Bioscience had 1 more articles in the media than Avalyn Pharma. MarketBeat recorded 6 mentions for Twist Bioscience and 5 mentions for Avalyn Pharma. Twist Bioscience's average media sentiment score of 1.16 beat Avalyn Pharma's score of -0.50 indicating that Twist Bioscience is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Avalyn Pharma 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Negative Twist Bioscience 3 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Avalyn Pharma (AVLN) Competitors

$28.06 +1.00 (+3.70%)

As of 04:00 PM Eastern

Compare

AVLN vs. INDV, TVTX, MANE, AMRX, and TWST

Should you buy Avalyn Pharma stock or one of its competitors? MarketBeat compares Avalyn Pharma with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Avalyn Pharma include Indivior (INDV), Travere Therapeutics (TVTX), MANE (MANE), Amneal Pharmaceuticals (AMRX), and Twist Bioscience (TWST). These companies are all part of the "pharmaceutical products" industry.

How does Avalyn Pharma compare to Indivior?

Avalyn Pharma (NASDAQ:AVLN) and Indivior (NASDAQ:INDV) are both pharmaceutical products companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, earnings, media sentiment, analyst recommendations, valuation, profitability, dividends and risk.

60.3% of Indivior shares are held by institutional investors. 0.7% of Indivior shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Indivior has a net margin of 19.44% compared to Avalyn Pharma's net margin of 0.00%. Avalyn Pharma's return on equity of 0.00% beat Indivior's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Avalyn Pharma	N/A	N/A	N/A
Indivior	19.44%	-219.26%	29.40%

In the previous week, Avalyn Pharma had 5 more articles in the media than Indivior. MarketBeat recorded 5 mentions for Avalyn Pharma and 0 mentions for Indivior. Indivior's average media sentiment score of 1.00 beat Avalyn Pharma's score of -0.50 indicating that Indivior is being referred to more favorably in the news media.

Company	Overall Sentiment
Avalyn Pharma	Negative
Indivior	Positive

Indivior has higher revenue and earnings than Avalyn Pharma.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Avalyn Pharma	N/A	N/A	N/A	N/A	N/A
Indivior	$1.24B	3.68	$210M	$1.95	19.17

Avalyn Pharma currently has a consensus target price of $59.00, indicating a potential upside of 110.26%. Indivior has a consensus target price of $39.33, indicating a potential upside of 5.20%. Given Avalyn Pharma's stronger consensus rating and higher probable upside, research analysts plainly believe Avalyn Pharma is more favorable than Indivior.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Avalyn Pharma	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	3.20
Indivior	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	3.00

Summary

Indivior beats Avalyn Pharma on 7 of the 12 factors compared between the two stocks.

How does Avalyn Pharma compare to Travere Therapeutics?

Avalyn Pharma (NASDAQ:AVLN) and Travere Therapeutics (NASDAQ:TVTX) are both pharmaceutical products companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, earnings, analyst recommendations, dividends, profitability, media sentiment, risk and valuation.

Avalyn Pharma has a net margin of 0.00% compared to Travere Therapeutics' net margin of -4.00%. Avalyn Pharma's return on equity of 0.00% beat Travere Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Avalyn Pharma	N/A	N/A	N/A
Travere Therapeutics	-4.00%	-26.16%	-3.71%

In the previous week, Travere Therapeutics had 14 more articles in the media than Avalyn Pharma. MarketBeat recorded 19 mentions for Travere Therapeutics and 5 mentions for Avalyn Pharma. Travere Therapeutics' average media sentiment score of 0.57 beat Avalyn Pharma's score of -0.50 indicating that Travere Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Avalyn Pharma	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Negative
Travere Therapeutics	7 Very Positive mention(s)	4 Positive mention(s)	6 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Avalyn Pharma has higher earnings, but lower revenue than Travere Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Avalyn Pharma	N/A	N/A	N/A	N/A	N/A
Travere Therapeutics	$490.73M	8.92	-$25.55M	-$0.23	N/A

Avalyn Pharma presently has a consensus price target of $59.00, indicating a potential upside of 110.26%. Travere Therapeutics has a consensus price target of $48.92, indicating a potential upside of 3.90%. Given Avalyn Pharma's stronger consensus rating and higher possible upside, analysts clearly believe Avalyn Pharma is more favorable than Travere Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Avalyn Pharma	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	3.20
Travere Therapeutics	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.69

Summary

Avalyn Pharma beats Travere Therapeutics on 6 of the 10 factors compared between the two stocks.

How does Avalyn Pharma compare to Veradermics?

Veradermics (NYSE:MANE) and Avalyn Pharma (NASDAQ:AVLN) are both manufacturing companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, profitability, valuation, analyst recommendations, dividends, media sentiment, earnings and risk.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Veradermics	N/A	N/A	N/A	N/A	N/A
Avalyn Pharma	N/A	N/A	N/A	N/A	N/A

Company	Net Margins	Return on Equity	Return on Assets
Veradermics	N/A	N/A	N/A
Avalyn Pharma	N/A	N/A	N/A

In the previous week, Avalyn Pharma had 1 more articles in the media than Veradermics. MarketBeat recorded 5 mentions for Avalyn Pharma and 4 mentions for Veradermics. Veradermics' average media sentiment score of -0.02 beat Avalyn Pharma's score of -0.50 indicating that Veradermics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Veradermics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
Avalyn Pharma	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Negative

Veradermics currently has a consensus target price of $109.00, suggesting a potential upside of 20.13%. Avalyn Pharma has a consensus target price of $59.00, suggesting a potential upside of 110.26%. Given Avalyn Pharma's stronger consensus rating and higher probable upside, analysts clearly believe Avalyn Pharma is more favorable than Veradermics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Veradermics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
Avalyn Pharma	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	3.20

Summary

Avalyn Pharma beats Veradermics on 4 of the 6 factors compared between the two stocks.

How does Avalyn Pharma compare to Amneal Pharmaceuticals?

Avalyn Pharma (NASDAQ:AVLN) and Amneal Pharmaceuticals (NASDAQ:AMRX) are both pharmaceutical products companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, earnings, media sentiment, analyst recommendations, dividends, valuation, profitability and institutional ownership.

31.8% of Amneal Pharmaceuticals shares are held by institutional investors. 17.3% of Amneal Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Avalyn Pharma currently has a consensus price target of $59.00, suggesting a potential upside of 110.26%. Amneal Pharmaceuticals has a consensus price target of $15.80, suggesting a potential upside of 15.24%. Given Avalyn Pharma's stronger consensus rating and higher probable upside, research analysts plainly believe Avalyn Pharma is more favorable than Amneal Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Avalyn Pharma	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	3.20
Amneal Pharmaceuticals	0 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.71

Amneal Pharmaceuticals has a net margin of 4.01% compared to Avalyn Pharma's net margin of 0.00%. Avalyn Pharma's return on equity of 0.00% beat Amneal Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Avalyn Pharma	N/A	N/A	N/A
Amneal Pharmaceuticals	4.01%	-313.96%	7.49%

In the previous week, Amneal Pharmaceuticals had 1 more articles in the media than Avalyn Pharma. MarketBeat recorded 6 mentions for Amneal Pharmaceuticals and 5 mentions for Avalyn Pharma. Amneal Pharmaceuticals' average media sentiment score of 0.30 beat Avalyn Pharma's score of -0.50 indicating that Amneal Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Avalyn Pharma	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Negative
Amneal Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Amneal Pharmaceuticals has higher revenue and earnings than Avalyn Pharma.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Avalyn Pharma	N/A	N/A	N/A	N/A	N/A
Amneal Pharmaceuticals	$3.02B	1.45	$72.06M	$0.38	36.08

Summary

Amneal Pharmaceuticals beats Avalyn Pharma on 8 of the 12 factors compared between the two stocks.

How does Avalyn Pharma compare to Twist Bioscience?

Avalyn Pharma (NASDAQ:AVLN) and Twist Bioscience (NASDAQ:TWST) are both pharmaceutical products companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, valuation, institutional ownership, risk, media sentiment, earnings, dividends and profitability.

Avalyn Pharma has a net margin of 0.00% compared to Twist Bioscience's net margin of -19.85%. Avalyn Pharma's return on equity of 0.00% beat Twist Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Avalyn Pharma	N/A	N/A	N/A
Twist Bioscience	-19.85%	-26.73%	-19.15%

In the previous week, Twist Bioscience had 1 more articles in the media than Avalyn Pharma. MarketBeat recorded 6 mentions for Twist Bioscience and 5 mentions for Avalyn Pharma. Twist Bioscience's average media sentiment score of 1.16 beat Avalyn Pharma's score of -0.50 indicating that Twist Bioscience is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Avalyn Pharma	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Negative
Twist Bioscience	3 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Avalyn Pharma currently has a consensus price target of $59.00, indicating a potential upside of 110.26%. Twist Bioscience has a consensus price target of $58.00, indicating a potential downside of 17.19%. Given Avalyn Pharma's stronger consensus rating and higher probable upside, analysts plainly believe Avalyn Pharma is more favorable than Twist Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Avalyn Pharma	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	3.20
Twist Bioscience	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75

Avalyn Pharma has higher earnings, but lower revenue than Twist Bioscience.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Avalyn Pharma	N/A	N/A	N/A	N/A	N/A
Twist Bioscience	$376.57M	11.58	-$77.67M	-$1.33	N/A

Summary

Avalyn Pharma beats Twist Bioscience on 6 of the 10 factors compared between the two stocks.

Get Avalyn Pharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AVLN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AVLN vs. The Competition

Export

Metric	Avalyn Pharma	Pharmaceutical Preparations Industry	Manufacturing Sector	NASDAQ Exchange
Market Cap	$1.24B	$948.41M	$4.26B	$11.99B
Dividend Yield	N/A	4.84%	9.68%	5.57%
P/E Ratio	N/A	1.47	21.73	23.74
Price / Sales	N/A	119.38	161.90	108.00
Price / Cash	N/A	20.06	46.51	37.25
Price / Book	N/A	7.84	30.05	6.78
Net Income	N/A	-$4.04M	$118.48M	$337.51M
7 Day Performance	5.25%	-2.89%	-3.24%	-2.72%
1 Month Performance	2.67%	4.38%	0.54%	1.87%
1 Year Performance	N/A	105.81%	12.35%	26.60%

Avalyn Pharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AVLN Avalyn Pharma	4.7579 of 5 stars	$28.06 +3.7%	$59.00 +110.3%	N/A	$1.24B	N/A	N/A	51	Positive News Earnings Report Quiet Period Expiration
INDV Indivior	2.1719 of 5 stars	$36.02 -1.6%	$39.33 +9.2%	+167.4%	$4.39B	$1.24B	18.47	1,051	Positive News
TVTX Travere Therapeutics	1.6857 of 5 stars	$47.18 -1.2%	$47.83 +1.4%	+199.0%	$4.39B	$490.73M	N/A	460
MANE MANE	N/A	$101.01 -1.8%	$100.00 -1.0%	N/A	$4.22B	N/A	N/A	19	Analyst Downgrade High Trading Volume
AMRX Amneal Pharmaceuticals	3.9791 of 5 stars	$13.17 +1.7%	$15.17 +15.2%	+80.4%	$4.20B	$3.02B	34.66	8,500

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:AVLN) was last updated on 6/8/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Avalyn Pharma (AVLN) Competitors

AVLN vs. INDV, TVTX, MANE, AMRX, and TWST

How does Avalyn Pharma compare to Indivior?

Summary

How does Avalyn Pharma compare to Travere Therapeutics?

Summary

How does Avalyn Pharma compare to Veradermics?

Summary

How does Avalyn Pharma compare to Amneal Pharmaceuticals?

Summary

How does Avalyn Pharma compare to Twist Bioscience?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AVLN vs. The Competition

Avalyn Pharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Avalyn Pharma (AVLN) Competitors

AVLN vs. INDV, TVTX, MANE, AMRX, and TWST

How does Avalyn Pharma compare to Indivior?

Do insiders and institutionals have more ownership in AVLN or INDV?

Is AVLN or INDV more profitable?

Does the media favor AVLN or INDV?

Which has higher valuation & earnings, AVLN or INDV?

Do analysts rate AVLN or INDV?

Summary

How does Avalyn Pharma compare to Travere Therapeutics?

Is AVLN or TVTX more profitable?

Does the media prefer AVLN or TVTX?

Which has preferable earnings and valuation, AVLN or TVTX?

Do analysts rate AVLN or TVTX?

Summary

How does Avalyn Pharma compare to Veradermics?

Which has better earnings and valuation, MANE or AVLN?

Is MANE or AVLN more profitable?

Does the media prefer MANE or AVLN?

Do analysts prefer MANE or AVLN?

Summary

How does Avalyn Pharma compare to Amneal Pharmaceuticals?

Do institutionals & insiders hold more shares of AVLN or AMRX?

Do analysts rate AVLN or AMRX?

Is AVLN or AMRX more profitable?

Does the media prefer AVLN or AMRX?

Which has preferable valuation & earnings, AVLN or AMRX?

Summary

How does Avalyn Pharma compare to Twist Bioscience?

Is AVLN or TWST more profitable?

Does the media favor AVLN or TWST?

Do analysts prefer AVLN or TWST?

Which has better earnings and valuation, AVLN or TWST?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AVLN vs. The Competition

Avalyn Pharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools